A new drug has been approved by the FDA in the fight against lung cancer. Tecentriq is being used by patients like Cornelius Bresnan, who had late-stage cancer.
Lung-MAP (SWOG S1400) is a multi-drug, multi-sub-study, biomarker-driven squamous cell lung cancer clinical trial that uses state-of-the-art genomic profiling to match patients to sub-studies testing investigational treatments that may target the genomic alterations, or mutations, found to be driving the growth of their cancer.
Professor Roy S. Herbst, M.D., Ph.D., Yale University, New Haven, will be recognized by The International Association for the Study of Lung Cancer with a Distinguished Award at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.
Immunotherapy continues to revolutionize the field of non–small cell lung cancer (NSCLC), with researchers now focusing on the optimal use of immune agents in the frontline setting.
New data presented at a cancer conference suggests that more than three in five Australian breast cancer survivors are overweight or obese – and that it’s likely to increase their risk of cancer returning.
The FDA granted approval to pembrolizumab for the first-line treatment of patients with metastatic non–small cell lung cancer whose tumors express programmed death ligand-1 as determined by an FDA–approved test.
The recent approval of pembrolizumab (Keytruda) in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) following progression on a platinum-based chemotherapy was a significant advancement for the disease. However, Barbara A. Burtness, MD, said, the approval of the PD-1 inhibitor only scratches the surface of the potential of immunotherapies in head and neck cancer.
Understanding how multiple myeloma develops and responds to therapies may be easier using a new mouse model developed at Yale University School of Medicine. The model supports the growth of cells derived from patients with multiple myeloma or the disease’s precursor states.
Researchers at the Yale School of Medicine have identified a chemical inhibitor that limits the growth of lung tumor cells. The inhibitor works by partially disrupting glycosylation, the addition of sugar chains to proteins.
In a recent study, senior author and Yale pathology professor Wang Min demonstrated that the tumors release substances called cytokines to attract macrophages.
Searching for more individual genes to predict responses to breast cancer therapy may not work, a new study suggests. Instead, scientists and clinicians need to pay attention to abnormalities in networks of genes, Yale researchers report in a paper published Oct. 20 in the journal Annals of Oncology.
Worsening depression symptoms are associated with shorter survival for lung cancer patients, particularly those in the early stages of disease, according to a new U.S. study.
To develop new approaches to cancer prevention, scientists have attempted to grow tumor cells from precursor states in animal models.
In a major breakthrough for ovarian and uterine cancers, Yale researchers have defined the genetic landscape of rare, highly aggressive tumors called carcinosarcomas (CSs), pointing the way to possible new treatments.
In a phase I clinical trial, patients with previously treated advanced non-small cell lung cancer (NSCLC) have showed initial response and disease control from the drug combination of ramucirumab and pembrolizumab. Roy S. Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven, will present the interim data of the clinical trial at the European Society for Medical Oncology (ESMO) Congress today.
After an extensive national search, Smilow Cancer Hospital and Yale Cancer Center (YCC) have announced that Charles S. Fuchs, MD, MPH, will become the new YCC director and physician-in-chief at Smilow Cancer Hospital, effective Jan. 1, 2017.
A Yale-led research team has identified a new blocking mechanism that acts like a dimmer switch and inhibits lung tumor cell growth.
In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had a net harm if they had a prior history of a heart attack.
A supplemental “boost” of radiation improves local control and provides an incremental benefit in decreasing breast cancer recurrence for patients with Ductal Carcinoma In Situ (DCIS) who receive whole breast radiation therapy radiation (WBRT) following lumpectomy, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer (NSCLC) with brain metastases to determine the best option for treatment.
The association between provider case volume and outcomes has long been suggested in cancer care. A Yale Cancer Center team has completed a review of outcomes for patients with locally advanced squamous cell head and neck cancers treated with intensity-modulated radiation therapy (IMRT) and found a distinct association between higher-volume treatment centers and improved overall survival.
In a recent study, a Yale Cancer Center team revealed that the addition of chemotherapy to postoperative treatment for adults with medulloblastoma improves survival.
Immunotherapy is a big change for head and neck cancer and there seems to be no doubt that there is activity for immunotherapies with pembrolizumab as well as nivolumab [Opdivo]” said Burtness, professor of Medicine at Yale Cancer Center.
In a recent study, a Yale Cancer Center team compared the performance of the four available PD-L1 assay tests. They found that one of the assays failed to reveal comparable levels of PD-L1, a tumor-promoting protein, while three others revealed comparable levels.
A team of researchers at Yale found that a treatment using bioadhesive nanoparticles loaded with a potent chemotherapy drug proved more effective and less toxic than conventional treatments for gynecological cancer.
Dr. Lieping Chen has launched a startup—NextCure—that is poised to lead to even more breakthrough treatments.
The new Phase I Clinical Trial Infusion Center will provide essential options for patients with advanced cancers seeking new therapies when standard treatments are no longer an option.
A Yale Cancer Center research team has identified that two genes, NR4A1 and ABC transporters, mark a distinct subset of quiescent T cells within human tissues, and have developed methods to mobilize them into circulation for potential application in adoptive T cell therapy of cancer.
A new nano-fabricated platform for observing brain cancer cells provides a much more detailed look at how the cells migrate and a more accurate post-surgery prognosis for brain cancer (glioblastoma) patients.
Using a novel cell culture approach, Yale Cancer Center researchers have discovered critical vulnerabilities in adenoid cystic carcinoma (ACC), a rare and lethal glandular cancer with a high recurrence rate and few treatment options. The findings, published April 15th in the journal.
Yale Cancer Center researchers have identified a gene in melanoma that can dramatically affect the growth of the disease. The findings, published in the journal Cell Reports, provide new insight into how melanoma grows and identifies a new target for treatment of melanoma and other cancers.
A team of researchers from Yale School of Public Health and Yale Cancer Center recently published a study in the Journal of Cancer Survivorship that addresses the needs of cancer survivors who are at least nine years beyond an initial diagnosis. In the Q &A below, authors Mary Playdon, Tara Sanft, and Brenda Cartmel, talk about how to better care for long-term survivors.
Yale Cancer Center researchers have identified what causes a third of all myelomas, a type of cancer affecting plasma cells. The findings, published in the Feb. 11 issue of the New England Journal of Medicine, could fundamentally change the way this cancer and others are treated.
One of the biggest questions about the treatment of multiple myeloma, a form of blood cancer, is why nearly all patients treated with current therapies eventually suffer relapse. A Yale Cancer Center study may have solved this mystery by identifying how cancer cells escape treatment, leading to recurrence. The findings were presented Dec. 6 at the 57th annual meeting of the American Hematologic Society in Orlando, Florida.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right